PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Ann Rheum Dis. 2007 November; 66(Suppl 3): iii1.
PMCID: PMC2095283

Advances in targeted therapies IX

The papers brought together in this supplement of the Annals of the Rheumatic Diseases constitute summaries of presentations from the seventh International Symposium on Advances in Targeted Therapies, which was held from 18 April until 22 April 2007. As such, these presentations represent the state of the art on the biology of mechanisms of action and pathophysiology of tumour necrosis factor (TNF) as well as other important mediators of inflammation. Current knowledge on the means and consequences of blocking TNF or other molecules or cellular mechanisms is presented as well.

We are grateful to Drs Crofford, Furst, Feldmann, Klareskog, Lipsky, Maini, Moreland and Weinblatt, the members of the Advisory Board of the Symposium, for their invaluable help towards the success of the conference, the ninth of a series of similar events planned for the future. We particularly wish to thank all speakers for their excellent presentations, most of which are summarised here in writing, and all participants who have actively contributed to the discussions. Finally, we also wish to thank the sponsors of this university‐driven event who have provided unrestricted educational grants that enabled us to invite the leading scientists in the field. Moreover, a rheumatological audience and the readers of this supplement have been able to obtain back‐to‐back information on the efficacy and safety of biological agents from representatives of the major companies involved with open discussion of issues arising regarding each agent when looked at individually and compared with others. It is also thankfully acknowledged that representatives of the FDA and EMEA actively participated in this symposium. Finally, based on the presentations and as a consequence of intensive discussions, a revised consensus statement on the application of biological agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis was formulated and we particularly have to thank Dr Furst for his guidance in this respect.

We hope that the readers of this supplement will enjoy the contributions as much as the participants seemed to enjoy the meeting.

The conference was organised under the sole responsibility of the departments of the Universities of Erlangen, Leiden and Vienna in collaboration with an advisory board consisting of the above‐mentioned colleagues from rheumatology departments of several US and European Universities. The following companies provided unrestricted educational grants for organising this conference: Abbott, Amgen, Bristol‐Myers Squibb, Genentech/Biogen Idec, Roche, UCB and Wyeth. The pharmaceutical industry had no part in the decisions regarding the specific programme and, with the exception of a few observers, participants were selected and solely invited by the organising committee. Several members of the advisory board and the members of the organising committee have obtained experience in the use of biological compounds in the course of their participation in clinical studies on these agents (for which the costs were defrayed by industry).


Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group